TY - JOUR T1 - Impact of Combination Chemotherapy with Itraconazole on Survival for Patients with Recurrent or Persistent Ovarian Clear Cell Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 2007 LP - 2014 VL - 34 IS - 4 AU - HIROSHI TSUBAMOTO AU - TAKASHI SONODA AU - MASAAKI YAMASAKI AU - KAYO INOUE Y1 - 2014/04/01 UR - http://ar.iiarjournals.org/content/34/4/2007.abstract N2 - Background: Recurrent ovarian clear cell carcinoma (CCC) rarely responds to cytotoxic agents. Itraconazole is a potent inhibitor of the P-glycoprotein efflux pump, angiogenesis, and the Hedgehog pathway. We evaluated the efficacy of chemotherapy with itraconazole for CCC. Patients and Methods: Medical charts of patients with CCC who had received chemotherapy with itraconazole were retrospectively reviewed. Results: Among nine patients with CCC, five had a history of progression with paclitaxel and carboplatin, and none had received prior treatment with bevacizumab or other targeted therapy. Eight patients received docetaxel (35 mg/m2, day 1) and carboplatin-based (area under the curve, 4 mg·min−1·mL−1; day 1) chemotherapy with an oral itraconazole solution (400 mg, days -2 to 2), repeated every two weeks. The response rate, median progression-free survival and overall survival were 44% (95% confidence interval [(CI)=12-77%], 544 days (95% CI=82-544 days) and 1,047 days (95% CI=462-1332 days), respectively. Conclusion: Chemotherapy with itraconazole is promising for patients with CCC. ER -